Crown, J. et al. 2025. TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis. Acta Oncologica. 64, (Jun. 2025), 751–760. DOI:https://doi.org/10.2340/1651-226X.2025.43143.